Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_assertion type Assertion NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_head.
- NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_assertion description "[Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_provenance.
- NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_assertion evidence source_evidence_literature NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_provenance.
- NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_assertion SIO_000772 16633151 NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_provenance.
- NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_assertion wasDerivedFrom befree-20140225 NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_provenance.
- NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_assertion wasGeneratedBy ECO_0000203 NP520974.RAsxdSMzX6kcnHZsPA5QsSWw_i__30K2IiaxzS-cnkOs0130_provenance.